Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Bipolar Disorder | 133 | 2023 | 5023 | 12.090 |
Why?
|
Antidepressive Agents | 57 | 2022 | 2836 | 6.130 |
Why?
|
Antimanic Agents | 29 | 2021 | 522 | 5.280 |
Why?
|
Antipsychotic Agents | 46 | 2022 | 3055 | 4.430 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 28 | 2022 | 1951 | 3.470 |
Why?
|
Obsessive-Compulsive Disorder | 12 | 2017 | 1442 | 2.910 |
Why?
|
Psychiatric Status Rating Scales | 43 | 2020 | 6028 | 2.480 |
Why?
|
Psychopharmacology | 6 | 2022 | 143 | 2.360 |
Why?
|
Depressive Disorder, Major | 26 | 2020 | 4606 | 2.110 |
Why?
|
Depressive Disorder | 24 | 2020 | 3743 | 2.090 |
Why?
|
Mood Disorders | 11 | 2014 | 1102 | 2.070 |
Why?
|
Valproic Acid | 15 | 2021 | 444 | 1.870 |
Why?
|
Psychiatry | 12 | 2022 | 1686 | 1.790 |
Why?
|
Affect | 10 | 2020 | 1475 | 1.700 |
Why?
|
Citalopram | 3 | 2021 | 404 | 1.680 |
Why?
|
Borderline Personality Disorder | 6 | 2015 | 735 | 1.640 |
Why?
|
Anticonvulsants | 23 | 2021 | 1907 | 1.430 |
Why?
|
Psychotropic Drugs | 6 | 2015 | 891 | 1.200 |
Why?
|
Lithium | 14 | 2020 | 603 | 1.190 |
Why?
|
Lithium Compounds | 7 | 2021 | 225 | 1.120 |
Why?
|
Psychomotor Agitation | 4 | 2019 | 287 | 1.090 |
Why?
|
Piperazines | 7 | 2015 | 2480 | 1.070 |
Why?
|
Risperidone | 9 | 2004 | 383 | 0.990 |
Why?
|
Existentialism | 5 | 2018 | 34 | 0.970 |
Why?
|
Benzodiazepines | 8 | 2015 | 1099 | 0.970 |
Why?
|
Thiazoles | 5 | 2015 | 1488 | 0.960 |
Why?
|
Antidepressive Agents, Second-Generation | 5 | 2021 | 503 | 0.930 |
Why?
|
Psychopathology | 2 | 2019 | 395 | 0.930 |
Why?
|
Lithium Carbonate | 7 | 2010 | 184 | 0.900 |
Why?
|
Drug Therapy, Combination | 33 | 2021 | 6478 | 0.900 |
Why?
|
Psychotherapy | 9 | 2015 | 1638 | 0.870 |
Why?
|
Triazines | 5 | 2014 | 316 | 0.860 |
Why?
|
Mental Disorders | 13 | 2020 | 6570 | 0.860 |
Why?
|
International Classification of Diseases | 5 | 2014 | 867 | 0.810 |
Why?
|
Clomipramine | 2 | 2017 | 54 | 0.750 |
Why?
|
Carbamazepine | 5 | 2014 | 229 | 0.720 |
Why?
|
Psychotic Disorders | 12 | 2020 | 3028 | 0.700 |
Why?
|
Psychological Theory | 2 | 2012 | 168 | 0.700 |
Why?
|
Cyclohexanecarboxylic Acids | 4 | 2001 | 143 | 0.700 |
Why?
|
Humans | 190 | 2023 | 739398 | 0.690 |
Why?
|
Randomized Controlled Trials as Topic | 16 | 2020 | 9812 | 0.680 |
Why?
|
Amines | 4 | 2001 | 277 | 0.660 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 4 | 2023 | 3636 | 0.650 |
Why?
|
Comorbidity | 18 | 2015 | 10362 | 0.640 |
Why?
|
Awareness | 7 | 2012 | 639 | 0.620 |
Why?
|
Galantamine | 2 | 2009 | 31 | 0.620 |
Why?
|
Advisory Committees | 5 | 2013 | 770 | 0.610 |
Why?
|
Treatment Outcome | 59 | 2021 | 62693 | 0.600 |
Why?
|
Basal Ganglia Diseases | 5 | 2006 | 149 | 0.600 |
Why?
|
Diagnostic Errors | 6 | 2011 | 1253 | 0.580 |
Why?
|
Isoxazoles | 3 | 2007 | 216 | 0.580 |
Why?
|
Sertraline | 2 | 2014 | 206 | 0.550 |
Why?
|
Pirenzepine | 3 | 2000 | 115 | 0.540 |
Why?
|
Temperament | 2 | 2023 | 281 | 0.540 |
Why?
|
Acetates | 4 | 2001 | 313 | 0.540 |
Why?
|
Depression | 8 | 2021 | 7689 | 0.540 |
Why?
|
Carcinogenicity Tests | 1 | 2015 | 40 | 0.530 |
Why?
|
gamma-Aminobutyric Acid | 5 | 2001 | 1127 | 0.510 |
Why?
|
Quinolones | 2 | 2008 | 365 | 0.500 |
Why?
|
Depression, Postpartum | 2 | 2017 | 335 | 0.480 |
Why?
|
Adult | 79 | 2023 | 213394 | 0.470 |
Why?
|
Research Design | 12 | 2020 | 5959 | 0.470 |
Why?
|
Double-Blind Method | 15 | 2021 | 11985 | 0.470 |
Why?
|
Terminology as Topic | 4 | 2017 | 1548 | 0.460 |
Why?
|
Emergency Services, Psychiatric | 2 | 2006 | 68 | 0.450 |
Why?
|
Trace Elements | 1 | 2014 | 198 | 0.430 |
Why?
|
Behavioral Symptoms | 1 | 2014 | 174 | 0.420 |
Why?
|
Dibenzothiazepines | 3 | 2001 | 104 | 0.410 |
Why?
|
Clozapine | 4 | 2000 | 498 | 0.410 |
Why?
|
Antidepressive Agents, Tricyclic | 3 | 2007 | 433 | 0.410 |
Why?
|
Acute Disease | 12 | 2021 | 7128 | 0.400 |
Why?
|
Dyskinesia, Drug-Induced | 2 | 2002 | 164 | 0.400 |
Why?
|
Affective Symptoms | 2 | 2011 | 406 | 0.400 |
Why?
|
Drug Prescriptions | 2 | 2014 | 1637 | 0.390 |
Why?
|
Male | 83 | 2021 | 349022 | 0.390 |
Why?
|
Neuropsychological Tests | 5 | 2018 | 6963 | 0.390 |
Why?
|
Drug Administration Schedule | 12 | 2021 | 4935 | 0.390 |
Why?
|
Fructose | 3 | 2001 | 287 | 0.380 |
Why?
|
Lithium Chloride | 1 | 2010 | 87 | 0.370 |
Why?
|
Female | 83 | 2021 | 378853 | 0.370 |
Why?
|
Second Messenger Systems | 2 | 2022 | 206 | 0.360 |
Why?
|
Diagnosis, Differential | 15 | 2017 | 12948 | 0.360 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2015 | 1374 | 0.350 |
Why?
|
Evidence-Based Medicine | 3 | 2011 | 3606 | 0.350 |
Why?
|
Meta-Analysis as Topic | 2 | 2005 | 1339 | 0.340 |
Why?
|
Substance-Related Disorders | 4 | 2013 | 4239 | 0.340 |
Why?
|
Serotonin Plasma Membrane Transport Proteins | 1 | 2010 | 323 | 0.330 |
Why?
|
Publication Bias | 1 | 2009 | 159 | 0.330 |
Why?
|
Hippocratic Oath | 1 | 2008 | 16 | 0.320 |
Why?
|
Bibliometrics | 1 | 2012 | 340 | 0.320 |
Why?
|
Middle Aged | 50 | 2021 | 212863 | 0.320 |
Why?
|
Nootropic Agents | 1 | 2009 | 160 | 0.320 |
Why?
|
Cyclothymic Disorder | 2 | 2023 | 41 | 0.310 |
Why?
|
Recurrence | 11 | 2015 | 8307 | 0.310 |
Why?
|
Societies, Medical | 3 | 2009 | 3739 | 0.310 |
Why?
|
Neuroprotective Agents | 1 | 2014 | 940 | 0.300 |
Why?
|
United States Food and Drug Administration | 1 | 2015 | 1584 | 0.300 |
Why?
|
Central Nervous System Stimulants | 3 | 2015 | 1146 | 0.290 |
Why?
|
Jaundice, Neonatal | 1 | 2007 | 67 | 0.290 |
Why?
|
Placebo Effect | 2 | 2021 | 503 | 0.290 |
Why?
|
Philosophy, Medical | 1 | 2007 | 80 | 0.290 |
Why?
|
Publishing | 2 | 2012 | 828 | 0.290 |
Why?
|
Pharmacogenetics | 1 | 2010 | 679 | 0.280 |
Why?
|
Peer Review, Research | 1 | 2009 | 327 | 0.280 |
Why?
|
Time Perception | 1 | 2006 | 84 | 0.270 |
Why?
|
Secondary Prevention | 7 | 2011 | 1516 | 0.270 |
Why?
|
Predictive Value of Tests | 6 | 2020 | 15036 | 0.260 |
Why?
|
Prevalence | 9 | 2023 | 15153 | 0.260 |
Why?
|
Observation | 2 | 2006 | 312 | 0.260 |
Why?
|
Internal Medicine | 1 | 2012 | 996 | 0.250 |
Why?
|
Cognition Disorders | 3 | 2009 | 4026 | 0.250 |
Why?
|
Psychoanalytic Therapy | 2 | 2004 | 230 | 0.250 |
Why?
|
Cholinesterase Inhibitors | 1 | 2006 | 239 | 0.240 |
Why?
|
Biomedical Research | 2 | 2012 | 3301 | 0.240 |
Why?
|
Severity of Illness Index | 14 | 2019 | 15511 | 0.230 |
Why?
|
Follow-Up Studies | 14 | 2021 | 38942 | 0.230 |
Why?
|
Cultural Diversity | 1 | 2007 | 357 | 0.220 |
Why?
|
History, 20th Century | 5 | 2017 | 2742 | 0.220 |
Why?
|
Disease Management | 1 | 2014 | 2448 | 0.220 |
Why?
|
Age of Onset | 6 | 2014 | 3263 | 0.220 |
Why?
|
Personality Inventory | 3 | 2023 | 1026 | 0.220 |
Why?
|
Irritable Mood | 4 | 2014 | 180 | 0.210 |
Why?
|
Adolescent | 18 | 2021 | 85405 | 0.200 |
Why?
|
Poverty | 1 | 2013 | 2626 | 0.200 |
Why?
|
Placebos | 4 | 2020 | 1678 | 0.200 |
Why?
|
Mind-Body Relations, Metaphysical | 1 | 2001 | 38 | 0.190 |
Why?
|
Urinary Tract Infections | 1 | 2007 | 766 | 0.190 |
Why?
|
Paroxetine | 2 | 1998 | 182 | 0.190 |
Why?
|
Akathisia, Drug-Induced | 3 | 2008 | 67 | 0.180 |
Why?
|
Dementia | 1 | 2014 | 2488 | 0.180 |
Why?
|
Young Adult | 10 | 2021 | 56255 | 0.180 |
Why?
|
Ambulatory Care | 8 | 2008 | 2711 | 0.180 |
Why?
|
Aftercare | 1 | 2006 | 858 | 0.180 |
Why?
|
Diagnosis, Dual (Psychiatry) | 2 | 2013 | 295 | 0.180 |
Why?
|
Intention to Treat Analysis | 1 | 2021 | 423 | 0.180 |
Why?
|
Kindling, Neurologic | 1 | 1999 | 30 | 0.170 |
Why?
|
Thioridazine | 1 | 1998 | 33 | 0.170 |
Why?
|
Long-Term Care | 3 | 2008 | 606 | 0.170 |
Why?
|
Polypharmacy | 1 | 2021 | 290 | 0.160 |
Why?
|
Community Mental Health Services | 3 | 2011 | 385 | 0.160 |
Why?
|
Serotonin Antagonists | 1 | 1999 | 146 | 0.160 |
Why?
|
Nortriptyline | 1 | 1998 | 80 | 0.160 |
Why?
|
Reproducibility of Results | 7 | 2020 | 19811 | 0.160 |
Why?
|
Primary Health Care | 2 | 2020 | 4537 | 0.160 |
Why?
|
Seasonal Affective Disorder | 1 | 1997 | 50 | 0.160 |
Why?
|
Fluvoxamine | 1 | 2017 | 74 | 0.150 |
Why?
|
Medical Records | 4 | 2006 | 1413 | 0.150 |
Why?
|
Dose-Response Relationship, Drug | 7 | 2008 | 10945 | 0.150 |
Why?
|
Ecosystem | 1 | 2021 | 467 | 0.150 |
Why?
|
Humanism | 1 | 2018 | 90 | 0.150 |
Why?
|
Personality | 2 | 2012 | 547 | 0.150 |
Why?
|
Suicide | 4 | 2020 | 1469 | 0.150 |
Why?
|
Mental Health Services | 2 | 2008 | 1641 | 0.150 |
Why?
|
Endpoint Determination | 2 | 2011 | 598 | 0.150 |
Why?
|
Time Factors | 6 | 2020 | 40050 | 0.130 |
Why?
|
Mass Screening | 3 | 2020 | 5265 | 0.130 |
Why?
|
Electric Injuries | 1 | 1995 | 26 | 0.130 |
Why?
|
Adaptive Immunity | 1 | 2020 | 709 | 0.130 |
Why?
|
Retrospective Studies | 21 | 2014 | 76631 | 0.130 |
Why?
|
Factor Analysis, Statistical | 1 | 2018 | 976 | 0.130 |
Why?
|
Emotions | 1 | 2006 | 2642 | 0.130 |
Why?
|
Paresthesia | 1 | 1995 | 159 | 0.120 |
Why?
|
Psychometrics | 3 | 2018 | 2995 | 0.120 |
Why?
|
GTP-Binding Proteins | 1 | 1999 | 972 | 0.120 |
Why?
|
Attitude to Health | 3 | 2010 | 2047 | 0.120 |
Why?
|
Nausea | 2 | 2008 | 656 | 0.120 |
Why?
|
South America | 1 | 2014 | 181 | 0.120 |
Why?
|
Drug Discovery | 1 | 2022 | 1056 | 0.120 |
Why?
|
ROC Curve | 3 | 2018 | 3526 | 0.120 |
Why?
|
Cross-Sectional Studies | 5 | 2020 | 24714 | 0.120 |
Why?
|
Regression Analysis | 4 | 2008 | 6452 | 0.110 |
Why?
|
Prospective Studies | 9 | 2013 | 53037 | 0.110 |
Why?
|
Practice Guidelines as Topic | 2 | 2008 | 7274 | 0.110 |
Why?
|
Anti-Anxiety Agents | 1 | 2015 | 390 | 0.110 |
Why?
|
Asia | 1 | 2014 | 604 | 0.110 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2022 | 2933 | 0.110 |
Why?
|
Tunisia | 1 | 2012 | 33 | 0.110 |
Why?
|
Sensitivity and Specificity | 5 | 2020 | 14740 | 0.110 |
Why?
|
History, Medieval | 1 | 2012 | 63 | 0.110 |
Why?
|
Edema | 1 | 1996 | 791 | 0.110 |
Why?
|
Epidemiologic Studies | 2 | 2014 | 677 | 0.100 |
Why?
|
Iraq | 1 | 2012 | 92 | 0.100 |
Why?
|
Pilot Projects | 4 | 2009 | 8275 | 0.100 |
Why?
|
Europe | 2 | 2014 | 3331 | 0.100 |
Why?
|
Drug Utilization | 3 | 2009 | 1181 | 0.100 |
Why?
|
Observer Variation | 1 | 2018 | 2589 | 0.100 |
Why?
|
Aged | 15 | 2020 | 162698 | 0.100 |
Why?
|
Behavioral Research | 1 | 2011 | 54 | 0.100 |
Why?
|
Glucocorticoids | 1 | 2020 | 2100 | 0.100 |
Why?
|
History, 21st Century | 1 | 2017 | 1534 | 0.100 |
Why?
|
Cholesterol | 1 | 2000 | 2900 | 0.100 |
Why?
|
MEDLINE | 1 | 2010 | 124 | 0.090 |
Why?
|
North America | 1 | 2014 | 1249 | 0.090 |
Why?
|
Concept Formation | 1 | 2011 | 158 | 0.090 |
Why?
|
Syndrome | 2 | 2009 | 3241 | 0.090 |
Why?
|
Hospitalization | 6 | 2013 | 10208 | 0.090 |
Why?
|
Sex Distribution | 2 | 2007 | 2296 | 0.090 |
Why?
|
Interview, Psychological | 1 | 2013 | 812 | 0.090 |
Why?
|
Students | 1 | 2020 | 1637 | 0.090 |
Why?
|
Weight Gain | 3 | 2006 | 2278 | 0.090 |
Why?
|
Triazoles | 1 | 1995 | 906 | 0.090 |
Why?
|
Cross-Over Studies | 1 | 2015 | 2030 | 0.090 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2020 | 1457 | 0.090 |
Why?
|
Cognition | 2 | 2004 | 6686 | 0.090 |
Why?
|
United States | 6 | 2020 | 69573 | 0.080 |
Why?
|
Age Factors | 4 | 2015 | 18349 | 0.080 |
Why?
|
Motivation | 1 | 1999 | 1965 | 0.080 |
Why?
|
Anxiety Disorders | 1 | 2000 | 2674 | 0.080 |
Why?
|
Self Concept | 2 | 2006 | 1024 | 0.080 |
Why?
|
Schizophrenic Psychology | 1 | 1995 | 1677 | 0.080 |
Why?
|
Wounds and Injuries | 1 | 2020 | 2394 | 0.080 |
Why?
|
Tranylcypromine | 1 | 2007 | 29 | 0.080 |
Why?
|
Frustration | 1 | 2007 | 20 | 0.080 |
Why?
|
Greece | 1 | 2008 | 343 | 0.080 |
Why?
|
Mianserin | 1 | 2007 | 52 | 0.070 |
Why?
|
Reality Testing | 1 | 2006 | 26 | 0.070 |
Why?
|
Lorazepam | 1 | 2008 | 146 | 0.070 |
Why?
|
Biological Psychiatry | 1 | 2007 | 25 | 0.070 |
Why?
|
Perceptual Distortion | 1 | 2006 | 35 | 0.070 |
Why?
|
Patient Selection | 2 | 2011 | 4211 | 0.070 |
Why?
|
Freedom | 1 | 2007 | 70 | 0.070 |
Why?
|
Cyclohexanols | 1 | 2007 | 127 | 0.070 |
Why?
|
Psychoanalytic Theory | 1 | 2007 | 143 | 0.070 |
Why?
|
Schizophrenia | 2 | 2015 | 6866 | 0.070 |
Why?
|
Models, Psychological | 2 | 2014 | 809 | 0.070 |
Why?
|
Risk Factors | 8 | 2013 | 71974 | 0.070 |
Why?
|
Parkinson Disease, Secondary | 1 | 2006 | 126 | 0.070 |
Why?
|
Spirituality | 1 | 2010 | 407 | 0.070 |
Why?
|
Dyskinesias | 1 | 2006 | 78 | 0.070 |
Why?
|
Empathy | 1 | 2010 | 471 | 0.070 |
Why?
|
History, 19th Century | 1 | 2008 | 721 | 0.070 |
Why?
|
Anxiety | 1 | 2020 | 4253 | 0.070 |
Why?
|
September 11 Terrorist Attacks | 1 | 2006 | 113 | 0.060 |
Why?
|
Bilirubin | 1 | 2007 | 415 | 0.060 |
Why?
|
Safety | 1 | 2010 | 1186 | 0.060 |
Why?
|
Clinical Trials as Topic | 4 | 2004 | 7897 | 0.060 |
Why?
|
Internal-External Control | 1 | 2006 | 362 | 0.060 |
Why?
|
Child Health Services | 1 | 2011 | 665 | 0.060 |
Why?
|
Blood Chemical Analysis | 1 | 2007 | 441 | 0.060 |
Why?
|
Case-Control Studies | 3 | 2020 | 21694 | 0.060 |
Why?
|
Urinalysis | 1 | 2007 | 370 | 0.060 |
Why?
|
Child | 5 | 2015 | 77033 | 0.060 |
Why?
|
Demography | 2 | 2007 | 1650 | 0.060 |
Why?
|
Patient Dropouts | 2 | 2004 | 419 | 0.060 |
Why?
|
Delayed-Action Preparations | 1 | 2007 | 962 | 0.060 |
Why?
|
Science | 1 | 2007 | 241 | 0.060 |
Why?
|
Attitude to Death | 1 | 2007 | 381 | 0.060 |
Why?
|
Neoplasms | 1 | 2013 | 21507 | 0.060 |
Why?
|
Periodicity | 1 | 2005 | 365 | 0.060 |
Why?
|
Sex Factors | 4 | 2008 | 10398 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2021 | 5272 | 0.060 |
Why?
|
False Negative Reactions | 1 | 2004 | 589 | 0.060 |
Why?
|
Vomiting | 1 | 2006 | 622 | 0.060 |
Why?
|
Telemedicine | 1 | 2020 | 2844 | 0.060 |
Why?
|
Resilience, Psychological | 1 | 2010 | 650 | 0.060 |
Why?
|
Analysis of Variance | 1 | 2012 | 6370 | 0.060 |
Why?
|
Electroconvulsive Therapy | 1 | 2008 | 469 | 0.050 |
Why?
|
Prognosis | 3 | 2011 | 28901 | 0.050 |
Why?
|
Dystonia | 1 | 2006 | 361 | 0.050 |
Why?
|
Canada | 1 | 2008 | 2021 | 0.050 |
Why?
|
Drug Resistance | 1 | 2008 | 1610 | 0.050 |
Why?
|
Task Performance and Analysis | 1 | 2007 | 780 | 0.050 |
Why?
|
Reaction Time | 1 | 2009 | 2097 | 0.050 |
Why?
|
Appointments and Schedules | 1 | 2006 | 415 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3143 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3248 | 0.050 |
Why?
|
Disclosure | 1 | 2007 | 735 | 0.050 |
Why?
|
Impulsive Behavior | 1 | 2003 | 315 | 0.050 |
Why?
|
Probability | 1 | 2007 | 2500 | 0.050 |
Why?
|
Drug Monitoring | 1 | 2007 | 961 | 0.050 |
Why?
|
Attention Deficit and Disruptive Behavior Disorders | 1 | 2003 | 303 | 0.050 |
Why?
|
Longitudinal Studies | 4 | 2010 | 13880 | 0.050 |
Why?
|
Haloperidol | 1 | 2002 | 397 | 0.050 |
Why?
|
Switzerland | 1 | 2001 | 249 | 0.050 |
Why?
|
Drug Tolerance | 1 | 2002 | 376 | 0.050 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2001 | 183 | 0.050 |
Why?
|
India | 1 | 2007 | 2189 | 0.050 |
Why?
|
Pandemics | 1 | 2020 | 8274 | 0.050 |
Why?
|
Survival Analysis | 2 | 2010 | 10247 | 0.040 |
Why?
|
Polymorphism, Genetic | 1 | 2010 | 4332 | 0.040 |
Why?
|
Public Health | 1 | 2013 | 2587 | 0.040 |
Why?
|
Economics, Pharmaceutical | 1 | 1999 | 87 | 0.040 |
Why?
|
Professional-Patient Relations | 1 | 2005 | 736 | 0.040 |
Why?
|
Memory | 1 | 2009 | 2161 | 0.040 |
Why?
|
Cost of Illness | 1 | 2009 | 1849 | 0.040 |
Why?
|
Methylprednisolone | 1 | 2020 | 388 | 0.040 |
Why?
|
Outpatients | 1 | 2006 | 1469 | 0.040 |
Why?
|
Cohort Studies | 4 | 2007 | 40389 | 0.040 |
Why?
|
Dyslipidemias | 1 | 2006 | 851 | 0.040 |
Why?
|
Risk Assessment | 2 | 2011 | 23294 | 0.040 |
Why?
|
Virginia | 1 | 1998 | 121 | 0.040 |
Why?
|
Defense Mechanisms | 1 | 1999 | 179 | 0.040 |
Why?
|
Fluoxetine | 1 | 2002 | 749 | 0.040 |
Why?
|
Personality Assessment | 1 | 2000 | 643 | 0.040 |
Why?
|
Logistic Models | 1 | 2013 | 13402 | 0.040 |
Why?
|
Bayes Theorem | 1 | 2006 | 2303 | 0.040 |
Why?
|
Dopamine Agonists | 1 | 2000 | 355 | 0.040 |
Why?
|
Remote Consultation | 1 | 2020 | 239 | 0.040 |
Why?
|
Delusions | 1 | 2000 | 300 | 0.040 |
Why?
|
Hallucinations | 1 | 2000 | 359 | 0.040 |
Why?
|
Culture | 2 | 2008 | 627 | 0.040 |
Why?
|
Videotape Recording | 1 | 1998 | 350 | 0.040 |
Why?
|
Chronic Disease | 1 | 2012 | 9133 | 0.040 |
Why?
|
Acetylcholine | 1 | 1999 | 622 | 0.040 |
Why?
|
Pedigree | 1 | 2004 | 4640 | 0.040 |
Why?
|
Public Sector | 1 | 1998 | 266 | 0.040 |
Why?
|
Research | 1 | 2005 | 2001 | 0.040 |
Why?
|
Phenotype | 2 | 2020 | 16301 | 0.030 |
Why?
|
Stress Disorders, Post-Traumatic | 3 | 2006 | 4220 | 0.030 |
Why?
|
STAT3 Transcription Factor | 1 | 2020 | 875 | 0.030 |
Why?
|
Hostility | 1 | 1996 | 189 | 0.030 |
Why?
|
Combined Modality Therapy | 2 | 2007 | 8605 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 2006 | 2749 | 0.030 |
Why?
|
Commitment of Mentally Ill | 1 | 1995 | 93 | 0.030 |
Why?
|
Circadian Rhythm | 1 | 2006 | 2614 | 0.030 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 1998 | 1580 | 0.030 |
Why?
|
Phototherapy | 1 | 1997 | 372 | 0.030 |
Why?
|
Developing Countries | 1 | 2007 | 2779 | 0.030 |
Why?
|
Anger | 1 | 1996 | 401 | 0.030 |
Why?
|
Protein Kinase C | 1 | 1999 | 1223 | 0.030 |
Why?
|
Patient Education as Topic | 1 | 2004 | 2275 | 0.030 |
Why?
|
Data Interpretation, Statistical | 1 | 2003 | 2716 | 0.030 |
Why?
|
Health Status | 2 | 2004 | 4013 | 0.030 |
Why?
|
Patient Readmission | 2 | 1998 | 3106 | 0.030 |
Why?
|
Patient Discharge | 1 | 2006 | 3286 | 0.030 |
Why?
|
Referral and Consultation | 1 | 2006 | 3514 | 0.030 |
Why?
|
Massachusetts | 1 | 2006 | 8669 | 0.030 |
Why?
|
Fatigue | 1 | 2020 | 1524 | 0.030 |
Why?
|
Disease Models, Animal | 1 | 2012 | 18003 | 0.030 |
Why?
|
Cost Savings | 1 | 1998 | 925 | 0.030 |
Why?
|
Family | 1 | 2003 | 3141 | 0.030 |
Why?
|
Hospitals, Psychiatric | 1 | 1994 | 332 | 0.030 |
Why?
|
Epilepsy, Temporal Lobe | 1 | 1996 | 402 | 0.030 |
Why?
|
Consensus | 2 | 2013 | 2913 | 0.030 |
Why?
|
Data Collection | 1 | 2001 | 3341 | 0.030 |
Why?
|
Registries | 1 | 2007 | 8039 | 0.030 |
Why?
|
Aggression | 1 | 1996 | 753 | 0.030 |
Why?
|
Cell Communication | 1 | 1999 | 1618 | 0.020 |
Why?
|
Animals | 2 | 2015 | 168368 | 0.020 |
Why?
|
Risk | 1 | 2003 | 9684 | 0.020 |
Why?
|
Genetic Markers | 1 | 1998 | 2630 | 0.020 |
Why?
|
Delphi Technique | 1 | 2013 | 770 | 0.020 |
Why?
|
Mental Recall | 1 | 1996 | 1201 | 0.020 |
Why?
|
Weight Loss | 1 | 2001 | 2589 | 0.020 |
Why?
|
Frontal Lobe | 1 | 1996 | 1409 | 0.020 |
Why?
|
Visual Perception | 1 | 1998 | 1418 | 0.020 |
Why?
|
Body Weight | 1 | 2000 | 4660 | 0.020 |
Why?
|
Synapses | 1 | 1999 | 1719 | 0.020 |
Why?
|
Phosphorylation | 1 | 2020 | 8416 | 0.020 |
Why?
|
Patient Admission | 1 | 1995 | 1383 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2006 | 5702 | 0.020 |
Why?
|
Life Change Events | 2 | 2006 | 936 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2007 | 25470 | 0.020 |
Why?
|
Iran | 1 | 2009 | 700 | 0.020 |
Why?
|
Drug Administration Routes | 1 | 2005 | 154 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 1998 | 5462 | 0.020 |
Why?
|
Pain | 1 | 2020 | 4923 | 0.020 |
Why?
|
Stress, Psychological | 1 | 1999 | 4212 | 0.010 |
Why?
|
Patient Compliance | 1 | 1994 | 2679 | 0.010 |
Why?
|
Morbidity | 1 | 2009 | 1763 | 0.010 |
Why?
|
Mass Media | 1 | 2006 | 301 | 0.010 |
Why?
|
Brief Psychiatric Rating Scale | 1 | 2002 | 108 | 0.010 |
Why?
|
Body Mass Index | 1 | 2000 | 12655 | 0.010 |
Why?
|
Antiparkinson Agents | 1 | 2002 | 183 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2008 | 1407 | 0.010 |
Why?
|
Length of Stay | 1 | 1994 | 6295 | 0.010 |
Why?
|
Suicide, Attempted | 1 | 2009 | 1213 | 0.010 |
Why?
|
Child, Preschool | 1 | 2003 | 40802 | 0.010 |
Why?
|
Benzothiazoles | 1 | 2000 | 250 | 0.010 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2008 | 993 | 0.010 |
Why?
|
Algorithms | 1 | 2000 | 13872 | 0.010 |
Why?
|
Treatment Refusal | 1 | 2002 | 419 | 0.010 |
Why?
|
Alzheimer Disease | 1 | 1999 | 7975 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2007 | 6516 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2009 | 7726 | 0.010 |
Why?
|
Propranolol | 1 | 1996 | 499 | 0.010 |
Why?
|
Odds Ratio | 1 | 2005 | 9846 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2007 | 12328 | 0.010 |
Why?
|
Neurologic Examination | 1 | 1996 | 932 | 0.010 |
Why?
|